Blog: Research

An opportunity to take part in a MS research study

19 November 2020

Do you have secondary progressive MS? Do you want to help with research?

MS research news

22 October 2020

Siponimod has been approved on the NHS as the first-ever oral treatment for people living with active secondary progressive MS in England and Wales.

MS research news

2 October 2020

An update about the latest MS research

MS Patients Switching from Tysabri to Other Therapies May Risk Disease Activity

26 February 2020

Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found.

Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial Reports

26 February 2020

Source Multiple Sclerosis News Today: AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show.

Sanofi MS drug results set stage for extensive late-stage testing

12 February 2020

Source With positive results from a mid-stage study in hand, Sanofi is pushing an experimental multiple sclerosis drug into an extensive late-stage research program comprised of four studies scheduled to begin in the middle of this year.

Gene Variants Linked to High Childhood BMI Point to Higher MS Risk, Study Finds

12 February 2020

Source Multiple Sclerosis News Today: Genetic variations that increase body mass index (BMI) in childhood are associated with a higher risk of multiple sclerosis (MS) regardless of a person’s vitamin D levels, a study found.

Multiple Sclerosis Drugs Might Not Need To Reach the Brain To Have Clinical Efficacy

12 February 2020

Source Technology Networks: Scientists from Trinity College Dublin have made an important discovery that could lead to more effective treatments for people living with multiple sclerosis (MS) and other autoimmune diseases such as psoriasis and rheumatoid arthritis.